Current and emerging pharmacotherapy for Gaucher disease in pediatric populations.

Richard Sam, Emory Ryan, Emily Daykin, Ellen Sidransky

Expert opinion on pharmacotherapy 2021 Aug

filter terms:

The past decades have witnessed a remarkable improvement in the health of patients with Gaucher disease, the inherited deficiency of the lysosomal enzyme glucocerebrosidase, resulting from the availability of enzyme replacement and substrate reduction therapies. Especially in pediatric populations, early diagnosis and initiation of treatment is essential to achieving optimal outcomes. The authors review the literature pertaining to the effectiveness of currently available therapies and describe new pharmacotherapies under development, especially for young patients. For pediatric patients with non-neuronopathic Gaucher disease, there may be new therapeutic options on the horizon in the form of gene therapy or small molecule glucocerebrosidase chaperones. These have the potential to result in a cure for systemic disease manifestations and/or to reduce the cost and convenience of treatment. For children with neuronopathic Gaucher disease, the challenge of targeting therapy to the central nervous system is being explored through new modalities including brain-targeted gene therapy, in-utero therapy, brain-penetrant small molecule chaperones, and other methods that convey enzyme across the blood-brain barrier. Indeed, these are exciting times for both pediatric patients with Gaucher disease and those with other lysosomal storage disorders.

Citation

Richard Sam, Emory Ryan, Emily Daykin, Ellen Sidransky. Current and emerging pharmacotherapy for Gaucher disease in pediatric populations. Expert opinion on pharmacotherapy. 2021 Aug;22(11):1489-1503